{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:20Z","timestamp":1790286920489,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10549-020-05914-w","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T17:03:05Z","timestamp":1599757385000},"page":"247-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1632-7791","authenticated-orcid":false,"given":"Pietro","family":"Sollena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Soupos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Kotteas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Voudouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros J.","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Apalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deilhes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"issue":"1","key":"5914_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5732\/cjc.010.10553","volume":"30","author":"L Yan","year":"2011","unstructured":"Yan L, Rosen N, Arteaga C (2011) Targeted cancer therapies. Chin J Cancer 30(1):1\u20134. https:\/\/doi.org\/10.5732\/cjc.010.10553","journal-title":"Chin J Cancer"},{"issue":"2","key":"5914_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"2","key":"5914_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","volume":"21","author":"JJ Gao","year":"2020","unstructured":"Gao JJ, Cheng J, Bloomquist E et al (2020) CDK 4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis. Lancet Oncol 21(2):250\u2013260. https:\/\/doi.org\/10.1016\/S1470-2045(19)30804-6","journal-title":"Lancet Oncol"},{"issue":"4","key":"5914_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","volume":"22","author":"YJ Choi","year":"2012","unstructured":"Choi YJ, Li X, Hydbring P et al (2012) The requirement for cyclin D function in tumor maintenance. Cancer Cell 22(4):438\u2013451. https:\/\/doi.org\/10.1016\/j.ccr.2012.09.015","journal-title":"Cancer Cell"},{"issue":"18","key":"5914_CR5","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738\u20131748","journal-title":"N Engl J Med"},{"issue":"7","key":"5914_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904\u2013915","journal-title":"Lancet Oncol"},{"issue":"4","key":"5914_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A, Harbeck N et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381(4):307\u2013316","journal-title":"N Engl J Med"},{"issue":"20","key":"5914_CR8","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"10226","key":"5914_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395(10226):817\u2013827. https:\/\/doi.org\/10.1016\/S0140-6736(20)30165-3","journal-title":"Lancet"},{"issue":"10","key":"5914_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V, Wu S, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126\u20131134. https:\/\/doi.org\/10.1634\/theoncologist.2013-0193","journal-title":"Oncologist"},{"issue":"9","key":"5914_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/14737140.2017.1355242","volume":"17","author":"S Lasheen","year":"2017","unstructured":"Lasheen S, Shohdy KS, Kassem L, Abdel-Rahman O (2017) Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther 17(9):851\u2013856. https:\/\/doi.org\/10.1080\/14737140.2017.1355242","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"5914_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77(1):1\u201313. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.048","journal-title":"J Am Acad Dermatol"},{"issue":"22","key":"5914_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.rmcr.2017.10.006","volume":"26","author":"P Zarogoulidis","year":"2017","unstructured":"Zarogoulidis P, Huang H, Tsiouda T et al (2017) Immunotherapy \u201cShock\u201d with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma. Respir Med Case Rep 26(22):283\u2013286. https:\/\/doi.org\/10.1016\/j.rmcr.2017.10.006","journal-title":"Respir Med Case Rep"},{"issue":"5","key":"5914_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","volume":"77","author":"J Dai","year":"2017","unstructured":"Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME (2017) Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol 77(5):902\u2013910.e2. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.044","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5914_CR15","first-page":"139","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"5914_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.12998\/wjcc.v3.i3.221","volume":"3","author":"GF Mohammed","year":"2015","unstructured":"Mohammed GF, Gomaa AH, Al-Dhubaibi MS (2015) Highlights in pathogenesis of vitiligo. World J Clin Cases 3(3):221\u2013230. https:\/\/doi.org\/10.12998\/wjcc.v3.i3.221","journal-title":"World J Clin Cases"},{"issue":"1","key":"5914_CR17","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.jaad.2017.08.028","volume":"78","author":"K Boniface","year":"2018","unstructured":"Boniface K, Dutriaux C, Prey S, Taieb A, Seneschal J (2018) Vitiligo-like lesions in patients receiving anti\u2013programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. J Am Acad Dermatol 78(1):e17\u2013e18. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.028","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"5914_CR18","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.3892\/mmr.2018.9299","volume":"18","author":"M Zhou","year":"2018","unstructured":"Zhou M, Lin F, Xu W, Jin R, Xu A (2018) Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. Mol Med Rep 18(3):3469\u20133475. https:\/\/doi.org\/10.3892\/mmr.2018.9299","journal-title":"Mol Med Rep"},{"issue":"10","key":"5914_CR19","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"3","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M (2018) Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 3(10):1758835918793326. https:\/\/doi.org\/10.1177\/1758835918793326","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"5914_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13555-020-00353-3","volume":"10","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Cohen PR (2020) Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. Dermatol Ther (Heidelb) 10(1):221\u2013229. https:\/\/doi.org\/10.1007\/s13555-020-00353-3","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"5914_CR21","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773\u2013781. https:\/\/doi.org\/10.1200\/JCO.2014.57.4756","journal-title":"J Clin Oncol"},{"issue":"1","key":"5914_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707","journal-title":"JAMA Dermatol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05914-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05914-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05914-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:48:56Z","timestamp":1631234936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05914-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5914"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05914-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Pietro Sollena reports personal fees for presentations during dermatologic meetings from Leo Pharma, Novartis, Pierre Fabre, Sanofi and reports personal fee for Advisory Board meeting from Almirall, outside the submitted work. Vasiliki Nikolaou reports personal fees for Advisory Board meetings from Takeda, Ipsen and personal fees for presentations during dermatologic meetings from Bristol Meyers Squiibb, Amgen, Boehringer Ingelheim Pharma, Novartis, outside the submitted work. Nikolaos Soupos reports personal fees for presentations during oncologic conferences from Roche, Ipsen, BMS and for Advisory Board Meetings from Roche, outside the submitted work. Elias Kotteas has no conflict of interest to report. Dimitra Voudouri has no conflict of interest to report. \u0391lexander Stratigos reports honorarium fees and\/or research support from Novartis, Roche, BMS, Abbvie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Davide Fattore has no conflict of interest to report. Maria Carmela Annunziata reports personal fees for presentations during dermatologic meetings from AbbVie, outside the submitted work. Armando Orlandi reports personal fees for public speaching during oncologic meetings from Novartis, Amgen, Lilly, Roche and reports personal fee for Advisory Board Meetings from Novartis, Lilly, Amgen and Roche, outside the submitted work. Lucia Di Nardo has no conflict of interest to report. Zoe Apalla reports personal fees for Advisory Board Meetings from AbbVie, Leo Pharma, Novartis, and Janssen, outside the submitted work. Gabriella Fabbrocini reports personal fees for Advisory Board Meetings from Almirall, AbbVie, Difa Cooper, Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sun Pharma and Janssen, outside the submitted work. Vincent Sibaud reports personal fees and honoraries for Advisory Board Meetings and symposia from Pierre Fabre, Novartis, BMS, Bayer, Sanofi outside the submitted work. Ketty Peris reports personal fees for Advisory Board Meetings from Almirall, AbbVie, Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}